Summary of GSK FY Conference Call - March 26, 2026 Company Overview - **Company**: GSK (NYSE:GSK) - **Event**: FY Conference Call - **Date**: March 26, 2026 Key Points Industry Focus - **Therapeutic Areas**: Respiratory, Immunology, Inflammation - **Key Product**: Camilpixant for chronic cough Chronic Cough Opportunity - **Prevalence**: Refractory chronic cough affects approximately 40 million people globally, characterized by cough lasting more than eight weeks [4][5] - **Patient Impact**: Patients experience debilitating symptoms, including severe coughing episodes that can lead to incontinence and rib fractures [4] - **Market Demand**: There is a significant demand for effective treatments, as existing options have been inadequate for decades [5] Camilpixant Development - **Phase III Trials**: Upcoming readouts for CALM-1 and CALM-2 trials, with CALM-1 completed and CALM-2 enrolling patients [13][15] - **Efficacy Benchmark**: A 15% reduction in cough frequency is considered clinically significant, based on comparisons with Merck's gefapixant [6][12] - **Selectivity and Tolerability**: Camilpixant is expected to have lower rates of taste disturbance compared to gefapixant, which had over 60% incidence of this side effect [11][12] - **Study Design**: Trials enriched for patients with over 20 coughs per hour to ensure robust data [15][19] Regulatory Considerations - **FDA Interaction**: Positive engagement with the FDA regarding trial design and endpoints, including the introduction of a Chronic Cough Diary for patient-reported outcomes [13][22] - **AdCom Expectations**: Uncertainty about whether an FDA Advisory Committee meeting will be required for camlipixant, depending on trial data [22] Bepirovirsen and Hepatitis B - **Approval Timeline**: On track to file for FDA approval in Q1 2026, with a focus on achieving a 15% functional cure rate [30][31] - **Clinical Importance**: A functional cure is linked to significant reductions in hepatocellular carcinoma risk [31] Market Potential - **Sales Projections**: Peak sales potential for chronic hepatitis B treatment estimated at $2 billion, with a focus on both developed and developing markets [36][37] - **Patient Population**: The diagnosed population is skewed towards markets like the U.S., with significant opportunities in low and middle-income countries [36] R&D Strategy - **Asset Acquisition**: GSK is focused on acquiring biologically validated assets with unmet needs, ensuring a strong market proposition [39][40] - **Differentiation**: Emphasis on selecting the right patient populations and responder phenotypes to enhance therapeutic profiles [43][44] AI in Drug Discovery - **AI Utilization**: GSK employs AI for drug design and development, particularly in understanding complex biological interactions and improving candidate selection [66][68] - **Data Integration**: The company is building comprehensive datasets to enhance decision-making in drug development [68][70] Respiratory Pipeline - **Diverse Portfolio**: GSK has a broad range of therapies for COPD, including multiple mechanisms targeting different aspects of the disease [61][62] - **Market Understanding**: Extensive data on respiratory diseases positions GSK favorably in the competitive landscape [63][65] Conclusion GSK is strategically positioned in the biopharma sector with a strong focus on addressing unmet medical needs in chronic cough and hepatitis B. The company is leveraging advanced trial designs, regulatory engagement, and innovative technologies like AI to enhance its R&D capabilities and market offerings.

Investment Rating - The report rates the industry as "Overweight" [4] Core Insights - The report provides a monthly tracking of global innovative drugs, highlighting advancements and investment opportunities in relevant frontier areas [2] - CagriSema's head-to-head data underperformed expectations, leading Novo Nordisk to accelerate the development of four next-generation weight loss assets [7][12] - The PD-1/VEGF dual antibody market is projected to exceed $100 billion, with several products expected to achieve peak sales of over $10 billion [19] - PROTAC and molecular glue technologies are showing positive progress across autoimmune, oncology, and CNS fields, with significant market potential [27] - Small nucleic acids are advancing towards multiple major indications, including weight loss and HBV treatment [27] Summary by Sections Weight Loss - Novo Nordisk's REDEFINE 4 study showed CagriSema resulted in a weight loss of 23.0% over 84 weeks compared to Tirzepatide's 25.5%, failing to meet non-inferiority expectations [7][8] - The company attributes the study's failure to the unusually high performance of Tirzepatide, suggesting that the open-label design may have biased participants [7] - Following the disappointing results, Novo Nordisk is expected to expedite the development of four next-generation weight loss assets [12] PD-1/VEGF Dual Antibodies - The PD-1/VEGF dual antibody market is anticipated to grow significantly, driven by longer treatment durations and survival benefits compared to PD-1 monotherapy [19] - The HARMONi-3 study has completed enrollment of 600 patients, with plans for an interim analysis in Q2 2026 [22] - The combination of PD-1/VEGF with new therapies like RAS inhibitors and ADCs is expected to expand treatment options and market reach [19] PROTAC/Molecular Glue - The report highlights the optimistic outlook for targeted protein degradation in autoimmune diseases, with promising early results from Kymera's KT-621 and Monte Rosa's NEK7 [27][28] - NEK7's mechanism targets upstream processes in inflammation, potentially offering a differentiated approach compared to existing therapies [28] - The early studies indicate competitive performance in reducing hsCRP levels, suggesting significant therapeutic advantages [31] Small Nucleic Acids - Early research on ARO-INHBE and ARO-ALK7 suggests potential for competitive weight loss effects and safety profiles when combined with low-dose GLP-1 [27] - The successful phase 3 results of bepirovirsen for HBV treatment are expected to be disclosed at EASL, with a focus on real-world data [27] In Vivo CAR-T - Eli Lilly's acquisition of Orna for $2.4 billion underscores the growing strategic interest in in vivo CAR-T therapies [27] - The report anticipates more clinical trial data in 2026 to validate the differentiation of in vivo CAR-T approaches [27]

Investment Rating - The report rates the industry as "Overweight" [4] Core Insights - The report highlights significant advancements and investment opportunities in the global innovative drug sector, particularly in weight loss, PD-1/VEGF dual antibodies, and PROTAC/molecular glue technologies [2][3] Summary by Sections Weight Loss - Novo Nordisk's REDEFINE 4 study showed that CagriSema resulted in a weight loss of 23.0% over 84 weeks compared to 25.5% for Tirzepatide, failing to meet the non-inferiority benchmark set by the company [7][8] - Following the disappointing results, Novo Nordisk is expected to accelerate the development of four next-generation weight loss assets, including Cagrilintide, Zenagamide, UBT251, and GLP-1/GIP/Amylin [12][17] PD-1/VEGF Dual Antibodies - The PD-1/VEGF dual antibody market is projected to exceed $100 billion, driven by longer duration of treatment and survival benefits compared to PD-1 monotherapy [19] - The HARMONi-3 study has completed enrollment of 600 patients, with plans for an interim analysis in Q2 2026, which may support accelerated approval discussions with the FDA [22][23] PROTAC/Molecular Glue - The report notes positive developments in PROTAC and molecular glue technologies, particularly in autoimmune diseases and oncology [27] - Monte Rosa's NEK7 molecular glue MRT-8102 has shown promising early results, potentially offering a competitive edge in reducing systemic inflammation [28][31] Small Nucleic Acids - Early studies of ARO-INHBE and ARO-ALK7 suggest potential for competitive weight loss effects and safety profiles when combined with low-dose GLP-1 [27] - The report emphasizes the shift from single-target RNAi to combination therapies for lipid reduction, marking a significant evolution in treatment strategies [27] In Vivo CAR-T - Eli Lilly's acquisition of Orna for $2.4 billion underscores the growing strategic interest in in vivo CAR-T therapies, which aim to simplify production while ensuring controlled expansion and safety [27]

Core Insights - Ionis Pharmaceuticals is entering a pivotal phase in 2025, transitioning into a fully integrated commercial-stage biotechnology company with strong initial launches of TRYNGOLZA and DAWNZERA [1][4] Commercial Performance - TRYNGOLZA generated $108 million in its first year, with a 56% quarter-over-quarter revenue increase, leading to raised peak sales expectations for the combined FCS/sHTG opportunity to over $2 billion [5][10] - DAWNZERA is positioned as the first RNA-targeted medicine for hereditary angioedema (HAE) prevention, resonating well with physicians and patients [11] Product Launch and Pipeline - The FDA accepted Ionis' supplemental NDA for olezarsen in severe hypertriglyceridemia (sHTG) with a priority review and a PDUFA date of June 30, positioning the company for a launch at the end of June or early July [4][6] - Ionis anticipates three product approvals and launches in 2026, including olezarsen for sHTG, zilganersen for Alexander disease, and bepirovirsen for chronic hepatitis B [5][8] Market Opportunity - The sHTG market is significant, affecting over 3 million people in the U.S., with an estimated 1 million high-risk patients eligible for olezarsen [8] - The initial launch focus for sHTG will target high-risk patients with triglycerides above 500 and those above 880, based on feedback from medical specialists [12] Financial Guidance - The priority review for olezarsen is expected to accelerate market entry by four months, leading to improved financial guidance, which will be updated during the end-of-first-quarter earnings call [13] Neurology Pipeline - Ionis is advancing its neurology franchise with the upcoming launch of zilganersen for Alexander disease, supported by positive phase III data [14] - The phase III program for obinutersen in Angelman syndrome is ongoing, with enrollment expected to complete this year [15]

Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: FY Conference Call on February 26, 2026 - **Key Speaker**: Brett Monia, CEO Core Industry and Company Insights - **FDA Acceptance**: The FDA accepted the supplemental NDA for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review status, setting a PDUFA date of June 30, 2026, which positions the company for a launch in late June or early July [2][3] - **Transformational Year**: 2025 was described as a pivotal year for Ionis, marking its transition to a fully integrated commercial-stage biotechnology company with successful independent launches of TRYNGOLZA for familial chylomicronemia syndrome (FCS) and DAWNZERA for hereditary angioedema (HAE) [3][4] - **Revenue Growth**: The company aims to achieve cash flow break-even by 2028, with expectations of accelerating revenue growth driven by its innovative pipeline [4][5] Product Pipeline and Launch Strategy - **Pipeline Success**: Ionis has had six positive Phase 3 readouts and four approved medicines in the last two and a half years, with 11 medicines in late-stage development [6][7] - **Upcoming Launches**: Expected product approvals and launches in 2026 include: - Olezarsen for sHTG - Zilganersen for Alexander disease - Bepirovirsen for chronic HBV [7][8] - **Market Focus**: Initial launch strategy for sHTG will prioritize patients with a history of acute pancreatitis and those with triglyceride levels above 880, as these patients are at the highest risk [29][30] Financial Projections - **Revenue Guidance**: The acceptance of the priority review for olezarsen is expected to improve revenue guidance, with updates to be provided in the Q1 earnings call [32] - **Peak Product Revenue**: The company anticipates over $4 billion in potential annual peak product revenue from its own medicines, with an additional $2 billion from partnered medicines, totaling over $6 billion in revenue [20][21] Neurology Portfolio - **Zilganersen Launch**: Zilganersen is positioned as Ionis' first independent launch in neurology, with positive Phase 3 data reported and an NDA submitted [19][36] - **Future Developments**: The company is also working on the Angelman syndrome program, which has received Breakthrough Therapy designation and is expected to complete enrollment in its Phase III study this year [20][39] Competitive Landscape and Innovation - **DAWNZERA's Competitive Edge**: DAWNZERA is noted for its compelling product profile, offering better efficacy, tolerability, and convenience compared to existing treatments for HAE [11][12] - **Follow-On Programs**: Ionis is exploring follow-on programs for its existing products to enhance dosing convenience and efficacy [33][34] Conclusion - **Outlook**: Ionis Pharmaceuticals is positioned for a transformative year in 2026, with multiple product launches and a strong pipeline that addresses significant unmet medical needs in cardiometabolic and neurological diseases [21][42]

Core Insights - Ionis Pharmaceuticals reported a narrower adjusted loss per share of $1.14 for Q4 2025, compared to the Zacks Consensus Estimate of a loss of $1.21, and an adjusted loss of 43 cents in the same period last year [1] - Total revenues for the quarter were $203 million, exceeding the Zacks Consensus Estimate of approximately $156 million, but reflecting a 10.6% decline year over year [2] Revenue Breakdown - The company has two wholly-owned marketed drugs: Tryngolza for familial chylomicronemia syndrome (FCS) and Dawnzera for hereditary angioedema, with Tryngolza launched in the U.S. in 2024 and Dawnzera approved in the EU in January 2026 [3] - Ionis has five partnered marketed drugs, including Spinraza and Qalsody in partnership with Biogen, and Wainua with AstraZeneca, generating royalties and distribution fees [4] Commercial Performance - Commercial revenues surged 64% year over year to $141 million, driven by Tryngolza's sales of $50 million, which increased by 56% year over year, and Dawnzera's $7 million in its first full quarter [5] - Spinraza royalties totaled $54 million, down 15.6% year over year, while Wainua royalties increased to $16 million from $10 million in the previous quarter [6] R&D and Costs - R&D revenues fell 56% year over year to $62 million but exceeded the Zacks Consensus Estimate of $25 million [7] - Adjusted operating costs rose 24.6% year over year to $375 million, with SG&A costs increasing by 52% to support commercialization efforts [9] Full-Year Results and Guidance - For 2025, total revenues reached $944 million, up 34% year over year, surpassing guidance, but included a one-time payment from Ono Pharmaceutical [10] - The company issued guidance for 2026, expecting revenues between $800 million and $825 million, which is below the Zacks Consensus Estimate of $867.3 million [11] Market Sentiment - The soft 2026 guidance led to a 5% decline in shares despite better-than-expected Q4 results, with concerns over slower product sales uptake for Tryngolza and Dawnzera [12] - Over the past year, Ionis shares have increased by 158.2%, significantly outperforming the industry growth of 3.5% [14] Pipeline Updates - Ionis is developing Tryngolza for severely elevated triglycerides (sHTG), with positive results from phase III studies, and has submitted a supplemental new drug application for expanded use [17] - Other candidates in the pipeline include zilganersen for Alexander disease and obudanersen for Angelman syndrome, with expected data releases in 2026 and 2027 respectively [19] Partnered Drug Developments - Ionis and AstraZeneca are developing Wainua for cardiomyopathy caused by hereditary TTR amyloidosis, with data expected in the second half of 2026 [20] - Bepirovirsen, developed in partnership with GSK for chronic hepatitis B, has shown positive phase III results, with regulatory filings anticipated in Q1 2026 [22]

Core Insights - Ionis Pharmaceuticals will host a live webcast on February 25, 2026, to discuss its fourth quarter and full year 2025 financial results and key program progress [1] - The company has a strong pipeline in neurology, cardiometabolic diseases, and other high-need areas, emphasizing its leadership in RNA-targeted medicines and gene editing [1] - Ionis achieved significant milestones in 2025, including two independent product launches and anticipates continued momentum and value creation in 2026 [1] Financial Results Webcast - The webcast is scheduled for February 25, 2026, at 11:30 a.m. Eastern Time [1] - A replay of the webcast will be available for a limited time [1] Company Achievements - Ionis has successfully executed its first two independent launches in 2025, marking a defining year for the company [1] - The company will provide a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] Product Approvals and Collaborations - The European Commission approved DAWNZERA™ (donidalorsen) for the prevention of hereditary angioedema in adults and adolescents aged 12 years and older [1] - Partner GSK announced positive topline results from Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, involving over 1,800 patients across 29 countries [1]

Financial Data and Key Metrics Changes - Sales increased by 7% to over GBP 32 billion, driven by Specialty Medicines which grew by 17% [2] - Core operating profit grew by 11%, and EPS was up by 12% [2] - Cash generation was strong at GBP 8.9 billion, supporting future investments and enabling a dividend upgrade to 66 pence [2][29] - Operating margin increased by 110 basis points, with total accretion at CER reaching 470 basis points over the last four years [30] - Cash generated from operations was GBP 8.9 billion, with free cash flow increasing to GBP 4 billion [31] Business Line Data and Key Metrics Changes - Specialty Medicines sales were up 17%, with significant contributions from respiratory immunology and inflammation, which saw an 18% increase [5] - Oncology sales surged by 43%, with Jemperli sales up by 89% [5][6] - HIV sales grew by 11%, driven by long-acting injectables and foundational oral regimens [9] - Vaccine sales were GBP 9.2 billion, up 2%, with Shingrix sales increasing by 8% [15] - GenMed sales slightly declined, with Trelegy showing strong growth offset by other respiratory products [17] Market Data and Key Metrics Changes - Nucala achieved 10 consecutive years of double-digit growth, with sales reaching GBP 2 billion [5] - The U.S. market for long-acting HIV treatments is projected to grow significantly, with Cabenuva growing by 42% [10] - Shingrix sales in Europe and international markets were strong, while U.S. sales faced challenges due to slowing immunization rates [15] - The U.S. retains a 74% market share in MenB vaccines, with positive signs for PenmenV [15] Company Strategy and Development Direction - The company aims to drive top-line growth by maximizing product launches and accelerating key assets in late-stage portfolios [3] - A focus on simplifying operations and leveraging AI and technology to enhance execution [4] - The strategy includes a commitment to long-acting treatments in HIV, with plans for Q6M treatment regimens [11][49] - Business development remains a core focus, with recent acquisitions aimed at enhancing the pipeline [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued profitable growth for 2026, with guidance for sales growth of 3%-5% and core operating profit growth of 7%-9% [32] - The company is positioned to navigate challenges such as the loss of exclusivity for dolutegravir and aims to evolve as a more product-centric organization [37] - Management highlighted the importance of scientific courage and agility in capitalizing on opportunities [37] Other Important Information - The company has secured 5 FDA approvals and initiated 7 new pivotal trials in 2025 [18] - The Zantac charge taken in 2024 impacted total results, but the settlement process is now materially complete [31] - The company plans to maintain a strong balance sheet with net debt to EBITDA stable at 1.3 times [32] Q&A Session Summary Question: Can you elaborate on R&D commercial strategy in COPD and asthma? - Management discussed the positioning of Nucala, Extensa, and other products in the COPD and asthma markets, emphasizing a strategic approach to address different patient populations [40][43] Question: When could we see the six-monthly treatment and what is the TAM increase? - Management confirmed that Q6M treatment is on track for phase 2B this year, with a significant addressable market for long-acting injectables in HIV treatment [49][51] Question: Update on the launch trajectory for Blenrep? - Initial feedback on Blenrep's launch has been positive, with a systematic opening of accounts and engagement with eye care professionals [58][66] Question: Is the reduction in R&D staff part of a broader program? - Management clarified that the reduction is part of a dynamic approach to resource allocation, focusing on areas with the best return potential [72] Question: How should we think about the launch curve for Extensa? - Management indicated a focus on bio-naive patients for Extensa, aiming to broaden the market and improve patient retention [72]

分组1 - Novo Nordisk is focusing on "commercial execution" and accelerating cash-pay sales for its oral GLP-1 drug for obesity, Wegovy, which was launched in January [1][2] - CEO Mike Doustdar acknowledged a challenging year for Novo, particularly due to Eli Lilly's increasing dominance in the obesity drug market and the company's struggles with Metsera [2] - Novo's strategy includes enhancing cash-pay services to capture market share in the obesity segment, recognizing the significant cash market opportunity that was previously underestimated [2][6] 分组2 - Eli Lilly's CEO David Ricks emphasized the importance of online channels for future product sales, catering to patients willing to pay cash for medications [4] - Novo has relaunched its online pharmacy and formed partnerships with direct-to-consumer channels to meet demand for its products [7] - Doustdar estimated that there are approximately 100 million people with obesity in the U.S., indicating a substantial market opportunity beyond the current patient base of 10-15 million [8] 分组3 - GSK is undergoing a leadership transition and has seen its share price increase by over 50% due to drug approvals and a broader sector upturn [15] - GSK's Chief Scientific Officer highlighted the potential of 15 upcoming drug launches, including an experimental medicine for hepatitis B that could serve as a "functional cure" for over 200 million patients [16][17] - The new hepatitis B treatment, bepirovirsen, has shown promise in late-stage trials, with full data expected to be presented at the EASL Congress in May [16]

Core Insights - GSK plc announced positive results from two phase III studies for its investigational chronic hepatitis B therapy, bepirovirsen [1][8] - Both studies met their primary endpoints, showing a statistically significant functional cure rate when bepirovirsen was combined with the current standard of care [2][8] - GSK plans to submit regulatory filings for bepirovirsen globally in the first quarter of 2026, aiming to position it as a finite six-month therapeutic option for chronic hepatitis B [5][8] Study Results - Treatment with bepirovirsen plus standard care demonstrated a meaningful functional cure rate in patients with baseline HBsAg of 3000 IU/ml or lower [2][3] - Functional cure is defined as the sustained loss of HBsAg and undetectable hepatitis B virus DNA for at least 24 weeks post-treatment [3] - GSK reported that bepirovirsen was particularly effective in patients with baseline HBsAg of 1000 IU/ml or lower, although specific numerical data was not disclosed [3][4] Market Potential - GSK estimates that chronic hepatitis B affects over 250 million people globally, indicating a significant market opportunity for bepirovirsen [5] - If approved, bepirovirsen could be the first therapy to achieve a meaningful functional cure for chronic hepatitis B [5] Stock Performance - Year to date, GSK shares have increased by 50%, outperforming the industry growth of 21% [7]